At week 8 , fenoverine was shown to be non-inferior to trimebutine ( treatment difference , 1.76 % ; 90 % CI , -10.30 -13.82 ; p = 0.81 ) ; 69.23 % ( 54 of 78 patients ) of patients taking fenoverine and 67.47 % ( 56 of 83 patients ) of patients taking trimebutine showed 30 % reduction in abdominal pain or discomfort compared to the baseline .